S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability

Cell Death and Disease

Volumn 5, Issue 2, 2014, Pages

  Buckley, N E ^a   D'Costa, Z ^a   Kaminska, M ^a   Mullan, P B ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

BRCA1; mutant p53; S100A2

Indexed keywords

HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN P53; PROTEIN P63; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEPLETION; S100A2 TUMOR SUPPRESSOR GENE; TUMOR SUPPRESSOR GENE; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BINDING SITES; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMOTACTIC FACTORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MCF-7 CELLS; MUTATION; PROMOTER REGIONS, GENETIC; PROTEIN STABILITY; RNA INTERFERENCE; S100 PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84896786491     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.31     Document Type: Article

References (54)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994 66-71.
2. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302: 643-646.
3. Yang Q, Sakurai T, Mori Iea. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer 2001; 92: 54-60.
4. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006; 25: 5854-5863.
5. Buckley NE, Conlon SJ, Jirstrom K, Kay EW, Crawford NT, O'Grady A et al. The {Delta}np63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer. Cancer Res 2011; 71: 1933-1944.
6. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B et al. A mutant-p53/ Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009; 137: 87-98.
7. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003 540-551.
8. Cross SS, Hamdy FC, Deloulme JC, Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 2005; 46: 256-269.
9. Wicki R, Franz C, Scholl FA, Heizmann CW, Schafer BW. Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site-specific hypermethylation. Cell Calcium 1997; 22: 243-254.
10. Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R. Expression of calciumbinding protein S100A2 in breast lesions. Br J Cancer 2000; 83: 1473-1479.
11. Lee SW, Tomasetto C, Swisshelm K, Keyomarsi K, Sager R. Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment. Proc Natl Acad Sci USA 1992; 89: 2504-2508.
12. van Dieck J, Teufel DP, Jaulent AM, Fernandez-Fernandez MR, Rutherford TJ, Wyslouch-Cieszynska A et al. Posttranslational modifications affect the interaction of S100 proteins with tumor suppressor p53. J Mol Biol 2009; 394: 922-930.
13. Mueller A, Schafer BW, Ferrari S, Weibel M, Makek M, Hochli M et al. The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J Biol Chem 2005; 280: 29186-29193.
14. Lapi E, Iovino A, Fontemaggi G, Soliera AR, Iacovelli S, Sacchi A et al. S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation. Oncogene 2006; 25: 3628-3637.
15. Kirschner RD, Sanger K, Muller GA, Engeland K. Transcriptional activation of the tumor suppressor and differentiation gene S100A2 by a novel p63-binding site. Nucleic Acids Res 2008; 36: 2969-2980.
16. Boni R, Burg G, Doguoglu A, Ilg EC, Schafer BW, Muller B et al. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions. Br J Dermatol 1997; 137: 39-43.
17. Shrestha P, Muramatsu Y, Kudeken W, Mori M, Takai Y, Ilg EC et al. Localization of Ca(2+)-binding S100 proteins in epithelial tumours of the skin. Virch Arch 1998; 432: 53-59.
18. Romano RA, Birkaya B, Sinha S. A functional enhancer of keratin14 is a direct transcriptional target of deltaNp63. J Invest Dermatol 2007; 127: 1175-1186.
19. Tan M, Heizmann CW, Guan K, Schafer BW, Sun Y. Transcriptional activation of the human S100A2 promoter by wild-Type p53. FEBS Lett 1999; 445: 265-268.
20. Tsai WC, Tsai ST, Jin YT, Wu LW. Cyclooxygenase-2 is involved in S100A2-mediated tumor suppression in squamous cell carcinoma. Mol Cancer Res 2006; 4: 539-547.
21. Antonini D, Rossi B, Han R, Minichiello A, Di Palma T, Corrado M et al. An autoregulatory loop directs the tissue-specific expression of p63 through a long-range evolutionarily conserved enhancer. Mol Cell Biol 2006; 26: 3308-3318.
22. Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 2008; 27: 3371-3383.
23. Shimamoto S, Kubota Y, Tokumitsu H, Kobayashi R. S100 proteins regulate the interaction of Hsp90 with cyclophilin 40 and FKBP52 through their tetratricopeptide repeats. FEBS Lett 2010; 584: 1119-1125.
24. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767.
25. Kennedy RD, Gorski JJ, Quinn JE, Stewart GE, James CR, Moore S et al. BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res 2005; 65: 10265-10272.
26. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-629.
27. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 2008; 22: 1337-1344.
28. Lee KC, Goh WL, Xu M, Kua N, Lunny D, Wong JS et al. Detection of the p53 response in zebrafish embryos using new monoclonal antibodies. Oncogene 2008; 27: 629-640.
29. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
30. Nagata Y, Anan T, Yoshida T, Mizukami T, Taya Y, Fujiwara T et al. The stabilization mechanism of mutant-Type p53 by impaired ubiquitination: The loss of wild-Type p53 function and the hsp90 association. Oncogene 1999; 18: 6037-6049.
31. Peng Y, Chen L, Li C, Lu W, Agrawal S, Chen J. Stabilization of the MDM2 oncoprotein by mutant p53. J Biol Chem 2001; 276: 6874-6878.
32. Peng Y, Chen L, Li C, Lu W, Chen J. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem 2001; 276: 40583-40590.
33. Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 2003; 300 344.
34. Esser C, Scheffner M, Hohfeld J. The chaperone-Associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem 2005; 280 27448.
35. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC et al. A high-Affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425 410.
36. King FW, Wawrzynow A, Hohfeld J, Zylicz M. Co-chaperones Bag-1, Hop and Hsp40 regulate Hsc70 and Hsp90 interactions with wild-Type or mutant p53. EMBO J 2001; 20 6305.
37. Shimamoto S, Takata M, Tokuda M, Oohira F, Tokumitsu H, Kobayashi R. Interactions of S100A2 and S100A6 with the tetratricopeptide repeat proteins, Hsp90/Hsp70-organizing protein and kinesin light chain. J Biol Chem 2008; 283: 28246-28258.
38. Shimamoto S, Kubota Y, Yamaguchi F, Tokumitsu H, Kobayashi R. Ca2+/S100 proteins act as upstream regulators of the chaperone-Associated ubiquitin ligase CHIP (C terminus of Hsc70-interacting protein). J Biol Chem 2013; 288: 7158-7168.
39. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011; 20: 79-91.
40. Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol 2011; 223 126.
41. Stecklein SR, Kumaraswamy E, Behbod F, Wang W, Chaguturu V, Harlan-Williams LM et al. BRCA1 and HSP90 cooperate in homologous and non-homologous DNA doublestrand-break repair and G2/M checkpoint activation. Proc Natl Acad Sci USA 2012; 109 13655.
42. Barrott JJ, Haystead TA. Hsp90, an unlikely ally in the war on cancer. FEBS J 2013; 280 1396.
43. Usmani SZ, Bona R, Li Z. 17 AAG for HSP90 inhibition in cancer-from bench to bedside. Curr Mol Med 2009; 9: 654-664.
44. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N et al. HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 2011; 17: 5132-5139.
45. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005 26729-26734.
46. Mullan PB, Hosey AM, Buckley NE, Quinn JE, Kennedy RD, Johnston PG et al. The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1-And interferon-gamma-mediated apoptosis. Oncogene 2005; 24: 5492-5501.
47. Tkocz D, Crawford NT, Buckley NE, Berry FB, Kennedy RD, Gorski JJ et al. BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers. Oncogene 2011; 31: 3667-3678.
48. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10 527.
49. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9: 671-675.
50. Buckley NE, Nic An Tsaoir CB, Blayney JK, Oram LC, Crawford NT, D'Costa ZC et al. BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers. Nucleic Acids Res 2013; 41 8614.
51. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE et al. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 2007; 99: 1683-1694.
52. Waddell N, Cocciardi S, Johnson J, Healey S, Marsh A, Riley J et al. Gene expression profiling of formalin-fixed, paraffin-embedded familial breast tumours using the whole genome-DASL assay. J Pathol 2010; 221: 452-461.
53. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006; 9: 121-132.
54. Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001; 344: 539-548.